Zoonotic Disease Treatment Market Size, Share and COVID-19 Impact Analysis, By Disease Type (Rabies, Malaria, Animal Flu, Ebola, Dengue, and Others), By Drug Class (Antibiotics, Antifungal, Anti-parasitic, Anti-bacterial, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2025-2032

A zoonotic disease is defined as a disease caused by the spread of infections from animals to humans. Parasites, fungi, and bacteria primarily cause zoonotic diseases. Malaria, rabies, animal flu, dengue, and others are some zoonotic diseases. The rise in the prevalence of malaria, dengue, animal flu and others has propelled the demand for the drugs used to treat zoonotic diseases.

• For instance, according to an article by the World Health Organization (WHO), around 100-400 million infections occur annually.

The prevalence of some zoonotic diseases, including malaria, dengue, and animal flu, has increased significantly over the past few years.

• For instance, according to the Pan American Health Organization, in 2022, around 4,110,465 cases of dengue fever were reported across the U.S. Moreover, around 4,099 deaths were reported owing to dengue.
• According to an article published by the World Health Organization (WHO), approximately 241 million malaria cases were reported globally in 2022.

Thus, the increasing patient population suffering from zoonotic diseases, along with the growing need to fulfil their unmet needs, is fueling the demand for effective zoonotic drugs. Market players are focusing R&D initiatives for developing new drugs. Moreover, government organizations have also increased the expenditure on research activities to develop the drugs used to treat dengue, malaria, animal flu, and other zoonotic diseases.

• Similarly, in March 2021, Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a compound which blocks an essential step in the malaria parasite life cycle. The development of the compound will help in the treatment of malaria.

The rise in research in the development of antimalarial and dengue drugs will lead to the entry of novel molecules for zoonotic therapy in the market, thereby driving the growth of the market.

Impact of COVID-19 on the Zoonotic Disease Treatment Market

The COVID-19 pandemic had a negative impact on the global zoonotic treatment market. Implementation of the lockdowns led to a decline in the availability of healthcare procedures and services unrelated to COVID-19. This was relevant for disease treatments such as zoonotic diseases, which hindered the treatment of the diseases. Additionally, the decline in the patient volume for the testing and diagnosing of zoonotic diseases, including dengue, rabies, ebola, and others, impacted the testing across several regions. Additionally, the resources used to treat zoonotic diseases were diverted to the fight against COVID-19.

For instance, according to an article published by the National Library of Medicine (NIH) in September 2022, the number of patients diagnosed with dengue declined by around 16% as compared to the previous year. Several companies manufacturing the drugs used to treat zoonotic drugs witnessed declining revenues due to decreased sales of their malaria and dengue diagnosis instruments and consumables during the pandemic.

• For instance, Novartis AG’s business segment Sandoz, which offers drugs for the treatment of malaria, witnessed a decline of -0.9% in 2020 as compared to the previous year.

Key Insights

The report will cover the following key insights:

• New Product Launches, Key Countries.
• Prevalence of Zoonotic Diseases by Key countries.
• Key Industry Developments (Mergers, Acquisitions, and Partnerships).
• Impact of COVID-19 on the market.

Analysis by Distribution Channel

The hospital pharmacy segment accounted for a significant global zoonotic treatment market share. The major share of the segment is attributed to the fact that the majority of the medications for the treatment can only be prescribed after thorough examinations by trained medical professionals at these institutions. Moreover, the government's rising initiative towards improving these institutions' facilities and infrastructure enables hospital pharmacies to gain preference among the people.

The online segment accounted for a significant CAGR during the forecast period. The segment's growth is attributed to the rising number of patients purchasing medicines through online distribution channels and the increasing number of e-pharmacy start-ups. These are some of the factors driving the segment's growth.

• For instance, according to a report published by NCBI in July 2022, India has about 50+ start-ups in the E-pharmacy space providing quality and affordable medicines to about 5,000,000 patients per month across the country. Such benefits are expected to boost segmental growth in the future.

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America constituted a significant share of the global zoonotic treatment market. The rise in the prevalence of zoonotic diseases, including malaria, dengue, and others, has accelerated the demand for zoonotic drugs.

• For instance, according to the Pan American Health Organization (PAHO), around 2,803,567 cases of dengue were reported in the U.S.

The increase in dengue and malaria cases has led to a rise in demand for zoonotic disease drugs. Thus, owing to these factors, the demand for zoonotic drugs is anticipated to rise in the coming years.

Europe constituted the second largest share in the zoonotic disease treatment market. The rise in the disease outbreak across Europe has led to an increase in the adoption of zoonotic disease treatment.

Asia Pacific is anticipated to grow significantly in the estimated forecast period. The increase in research and development activities across China, Japan, and India is primarily driving the market growth in the region.

Key Players Covered

The report includes the profiles of key players, including Novartis AG, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Strides Pharma Science Limited, Sarepta Therapeutics, Inc., Macleods Pharmaceuticals Ltd., and Lupin.

Segmentation

Key Industry Developments

• July 2022: Mosquirix, a vaccine developed by GlaxoSmithKline (GSK), is said to be the world's first antimalarial vaccine launched in three African countries, such as Ghana, Kenya, and Malawi under the Gavi vaccine project with the support of the Gates Foundation.
• December 2021: Zydus Cadila received an orphan drug designation for ZY19489 from the U.S. Food and Drugs Administration (FDA). It is used to treat malaria.